Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

CNS-Specific Synthesis of Interleukin 23 Induces a Progressive Cerebellar Ataxia and the Accumulation of Both T and B Cells in the Brain: Characterization of a Novel Transgenic Mouse Model.

Nitsch L, Zimmermann J, Krauthausen M, Hofer MJ, Saggu R, Petzold GC, Heneka MT, Getts DR, Becker A, Campbell IL, Müller M.

Mol Neurobiol. 2019 Jun 2. doi: 10.1007/s12035-019-1640-0. [Epub ahead of print]

PMID:
31154574
2.

Experimental severe malaria is resolved by targeting newly-identified monocyte subsets using immune-modifying particles combined with artesunate.

Niewold P, Cohen A, van Vreden C, Getts DR, Grau GE, King NJC.

Commun Biol. 2018 Dec 13;1:227. doi: 10.1038/s42003-018-0216-2. eCollection 2018.

3.

Overcoming challenges in treating autoimmuntity: Development of tolerogenic immune-modifying nanoparticles.

Pearson RM, Podojil JR, Shea LD, King NJC, Miller SD, Getts DR.

Nanomedicine. 2019 Jun;18:282-291. doi: 10.1016/j.nano.2018.10.001. Epub 2018 Oct 21. Review.

PMID:
30352312
4.

Tolerogenic Ag-PLG nanoparticles induce tregs to suppress activated diabetogenic CD4 and CD8 T cells.

Prasad S, Neef T, Xu D, Podojil JR, Getts DR, Shea LD, Miller SD.

J Autoimmun. 2018 May;89:112-124. doi: 10.1016/j.jaut.2017.12.010. Epub 2017 Dec 16.

5.

Controlled Delivery of Single or Multiple Antigens in Tolerogenic Nanoparticles Using Peptide-Polymer Bioconjugates.

Pearson RM, Casey LM, Hughes KR, Wang LZ, North MG, Getts DR, Miller SD, Shea LD.

Mol Ther. 2017 Jul 5;25(7):1655-1664. doi: 10.1016/j.ymthe.2017.04.015. Epub 2017 May 5.

6.

Enhanced viral clearance and reduced leukocyte infiltration in experimental herpes encephalitis after intranasal infection of CXCR3-deficient mice.

Zimmermann J, Hafezi W, Dockhorn A, Lorentzen EU, Krauthausen M, Getts DR, Müller M, Kühn JE, King NJC.

J Neurovirol. 2017 Jun;23(3):394-403. doi: 10.1007/s13365-016-0508-6. Epub 2017 Jan 23.

PMID:
28116674
7.

Harnessing Nanoparticles for Immune Modulation: (Trends in Immunology 36, 419-427; July 2016).

Getts DR, Shea LD, Miller SD, King NJC.

Trends Immunol. 2016 Oct;37(10):715. doi: 10.1016/j.it.2016.08.003. Epub 2016 Sep 7. No abstract available.

PMID:
27614797
8.

Biodegradable antigen-associated PLG nanoparticles tolerize Th2-mediated allergic airway inflammation pre- and postsensitization.

Smarr CB, Yap WT, Neef TP, Pearson RM, Hunter ZN, Ifergan I, Getts DR, Bryce PJ, Shea LD, Miller SD.

Proc Natl Acad Sci U S A. 2016 May 3;113(18):5059-64. doi: 10.1073/pnas.1505782113. Epub 2016 Apr 18.

9.

Deficient Natural Killer Dendritic Cell Responses Underlay the Induction of Theiler's Virus-Induced Autoimmunity.

Chastain EM, Getts DR, Miller SD.

MBio. 2015 Aug 4;6(4):e01175. doi: 10.1128/mBio.01175-15.

10.

Harnessing nanoparticles for immune modulation.

Getts DR, Shea LD, Miller SD, King NJ.

Trends Immunol. 2015 Jul;36(7):419-27. doi: 10.1016/j.it.2015.05.007. Epub 2015 Jun 15. Review. Erratum in: Trends Immunol. 2016 Oct;37(10 ):715.

11.

Editorial to special issue: monocytes in homeostasis and disease.

Getts DR.

Cell Immunol. 2014 Sep-Oct;291(1-2):1-2. doi: 10.1016/j.cellimm.2014.10.001. Epub 2014 Oct 24. No abstract available.

PMID:
25438692
12.

Defective inflammatory monocyte development in IRF8-deficient mice abrogates migration to the West Nile virus-infected brain.

Terry RL, Deffrasnes C, Getts DR, Minten C, van Vreden C, Ashhurst TM, Getts MT, Xie RD, Campbell IL, King NJ.

J Innate Immun. 2015;7(1):102-12. doi: 10.1159/000365972. Epub 2014 Sep 23.

13.

First-in-human study of the safety and efficacy of TOL101 induction to prevent kidney transplant rejection.

Flechner SM, Mulgoankar S, Melton LB, Waid TH, Agarwal A, Miller SD, Fokta F, Getts MT, Frederick TJ, Herrman JJ, Puisis JP, O'Toole L, Sung R, Shihab F, Wiseman AC, Getts DR.

Am J Transplant. 2014 Jun;14(6):1346-55. doi: 10.1111/ajt.12698. Epub 2014 Apr 17.

14.

The pharmacokinetics and pharmacodynamics of TOL101, a murine IgM anti-human αβ T cell receptor antibody, in renal transplant patients.

Getts DR, Kramer WG, Wiseman AC, Flechner SM.

Clin Pharmacokinet. 2014 Jul;53(7):649-57. doi: 10.1007/s40262-014-0138-1.

PMID:
24668001
15.

A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease.

Hunter Z, McCarthy DP, Yap WT, Harp CT, Getts DR, Shea LD, Miller SD.

ACS Nano. 2014 Mar 25;8(3):2148-60. doi: 10.1021/nn405033r. Epub 2014 Feb 27.

16.

Antiviral macrophage responses in flavivirus encephalitis.

Ashhurst TM, Vreden Cv, Munoz-Erazo L, Niewold P, Watabe K, Terry RL, Deffrasnes C, Getts DR, Cole King NJ.

Indian J Med Res. 2013 Nov;138(5):632-47. Review.

17.

Therapeutic inflammatory monocyte modulation using immune-modifying microparticles.

Getts DR, Terry RL, Getts MT, Deffrasnes C, Müller M, van Vreden C, Ashhurst TM, Chami B, McCarthy D, Wu H, Ma J, Martin A, Shae LD, Witting P, Kansas GS, Kühn J, Hafezi W, Campbell IL, Reilly D, Say J, Brown L, White MY, Cordwell SJ, Chadban SJ, Thorp EB, Bao S, Miller SD, King NJ.

Sci Transl Med. 2014 Jan 15;6(219):219ra7. doi: 10.1126/scitranslmed.3007563.

18.

Exploiting apoptosis for therapeutic tolerance induction.

Getts DR, McCarthy DP, Miller SD.

J Immunol. 2013 Dec 1;191(11):5341-6. doi: 10.4049/jimmunol.1302070. Review.

19.

The bacteriostatic protein lipocalin 2 is induced in the central nervous system of mice with west Nile virus encephalitis.

Noçon AL, Ip JP, Terry R, Lim SL, Getts DR, Müller M, Hofer MJ, King NJ, Campbell IL.

J Virol. 2014 Jan;88(1):679-89. doi: 10.1128/JVI.02094-13. Epub 2013 Oct 30.

20.

Virus infection, antiviral immunity, and autoimmunity.

Getts DR, Chastain EM, Terry RL, Miller SD.

Immunol Rev. 2013 Sep;255(1):197-209. doi: 10.1111/imr.12091. Review.

21.

Manipulating T cell-mediated pathology: targets and functions of monoclonal antibody immunotherapy.

Martin A, Tisch RM, Getts DR.

Clin Immunol. 2013 Jul;148(1):136-47. doi: 10.1016/j.clim.2013.04.011. Epub 2013 Apr 28. Review.

22.

Inflammatory monocytes and the pathogenesis of viral encephalitis.

Terry RL, Getts DR, Deffrasnes C, van Vreden C, Campbell IL, King NJ.

J Neuroinflammation. 2012 Dec 17;9:270. doi: 10.1186/1742-2094-9-270. Review.

23.

Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis.

Getts DR, Martin AJ, McCarthy DP, Terry RL, Hunter ZN, Yap WT, Getts MT, Pleiss M, Luo X, King NJ, Shea LD, Miller SD.

Nat Biotechnol. 2012 Dec;30(12):1217-24. doi: 10.1038/nbt.2434. Epub 2012 Nov 18.

24.

Targeted blockade in lethal West Nile virus encephalitis indicates a crucial role for very late antigen (VLA)-4-dependent recruitment of nitric oxide-producing macrophages.

Getts DR, Terry RL, Getts MT, Müller M, Rana S, Deffrasnes C, Ashhurst TM, Radford J, Hofer M, Thomas S, Campbell IL, King NJ.

J Neuroinflammation. 2012 Oct 30;9:246. doi: 10.1186/1742-2094-9-246.

25.

Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells.

Getts DR, Turley DM, Smith CE, Harp CT, McCarthy D, Feeney EM, Getts MT, Martin AJ, Luo X, Terry RL, King NJ, Miller SD.

J Immunol. 2011 Sep 1;187(5):2405-17. doi: 10.4049/jimmunol.1004175. Epub 2011 Aug 5.

26.

Current landscape for T-cell targeting in autoimmunity and transplantation.

Getts DR, Shankar S, Chastain EM, Martin A, Getts MT, Wood K, Miller SD.

Immunotherapy. 2011 Jul;3(7):853-70. doi: 10.2217/imt.11.61. Review.

27.

Have we overestimated the benefit of human(ized) antibodies?

Getts DR, Getts MT, McCarthy DP, Chastain EM, Miller SD.

MAbs. 2010 Nov-Dec;2(6):682-94. Epub 2010 Nov 1. Review.

28.

Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis.

Quintana A, Müller M, Frausto RF, Ramos R, Getts DR, Sanz E, Hofer MJ, Krauthausen M, King NJ, Hidalgo J, Campbell IL.

J Immunol. 2009 Aug 1;183(3):2079-88. doi: 10.4049/jimmunol.0900242. Epub 2009 Jul 13.

29.

ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms.

Luo X, Pothoven KL, McCarthy D, DeGutes M, Martin A, Getts DR, Xia G, He J, Zhang X, Kaufman DB, Miller SD.

Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14527-32. doi: 10.1073/pnas.0805204105. Epub 2008 Sep 16.

30.

Ly6c+ "inflammatory monocytes" are microglial precursors recruited in a pathogenic manner in West Nile virus encephalitis.

Getts DR, Terry RL, Getts MT, Müller M, Rana S, Shrestha B, Radford J, Van Rooijen N, Campbell IL, King NJ.

J Exp Med. 2008 Sep 29;205(10):2319-37. doi: 10.1084/jem.20080421. Epub 2008 Sep 8.

31.

Endoplasmic reticulum stress response as a potential therapeutic target in multiple sclerosis.

Getts MT, Getts DR, Kohm AP, Miller SD.

Therapy. 2008 Sep 1;5(5):631-640.

32.

Viruses and the immune system: their roles in seizure cascade development.

Getts DR, Balcar VJ, Matsumoto I, Müller M, King NJ.

J Neurochem. 2008 Mar;104(5):1167-76. doi: 10.1111/j.1471-4159.2007.05171.x. Epub 2008 Jan 17. Review.

33.

Role of IFN-gamma in an experimental murine model of West Nile virus-induced seizures.

Getts DR, Matsumoto I, Müller M, Getts MT, Radford J, Shrestha B, Campbell IL, King NJ.

J Neurochem. 2007 Nov;103(3):1019-30. Epub 2007 Sep 5.

34.

CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system.

Müller M, Carter SL, Hofer MJ, Manders P, Getts DR, Getts MT, Dreykluft A, Lu B, Gerard C, King NJ, Campbell IL.

J Immunol. 2007 Sep 1;179(5):2774-86.

35.

Immunopathology of flavivirus infections.

King NJ, Getts DR, Getts MT, Rana S, Shrestha B, Kesson AM.

Immunol Cell Biol. 2007 Jan;85(1):33-42. Epub 2006 Dec 5. Review.

PMID:
17146465
36.

Coordinated regulation and widespread cellular expression of interferon-stimulated genes (ISG) ISG-49, ISG-54, and ISG-56 in the central nervous system after infection with distinct viruses.

Wacher C, Müller M, Hofer MJ, Getts DR, Zabaras R, Ousman SS, Terenzi F, Sen GC, King NJ, Campbell IL.

J Virol. 2007 Jan;81(2):860-71. Epub 2006 Nov 1.

Supplemental Content

Loading ...
Support Center